Ocugen (NASDAQ:OCGN) Sees Unusually-High Trading Volume – Here’s Why

Ocugen, Inc. (NASDAQ:OCGN) saw unusually-strong trading volume on Tuesday . Approximately 6,755,595 shares were traded during trading, a decline of 13% from the previous session’s volume of 7,768,395 shares.The stock last traded at $1.8150 and had previously closed at $2.10.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Phase 2 topline shows efficacy and safety: The medium (optimal) dose produced a statistically significant 31% reduction in GA lesion growth at 12 months versus control, with no OCU410‑related serious adverse events reported — a clear positive clinical readout. GlobeNewswire Release
• Positive Sentiment: Commercial potential and next steps: Management highlighted a potential ~2x benefit vs. existing therapies, plans a Phase 3 registrational trial in Q3 2026 (up to ~300 subjects, adaptive design), and positions OCU410 as a one‑time gene therapy — factors that support sizable long‑term upside if confirmed. QuiverQuant Summary
• Positive Sentiment: Index inclusion raises visibility: Ocugen was added to the S&P Biotechnology Select Industry Index, which can increase passive/fund demand and broader investor attention. Yahoo Finance
• Neutral Sentiment: Investor presentation/webcast: Ocugen hosted a webcast with KOLs and management to discuss the full Phase 2 dataset, providing more detail for analysts and investors to digest. Webcast Notice
• Neutral Sentiment: Market positioning and recent run-up: Recent strong gains have already repriced expectations for OCU410; pieces discussing valuation and whether the rally is extended may temper near‑term buying. Yahoo: Is It Too Late?
• Negative Sentiment: Immediate sell‑side reaction and share decline: Despite positive topline data, the stock fell as some investors took profits and others remain cautious until larger, confirmatory Phase 3 data are available — headlines flagged the drop. Seeking Alpha
• Negative Sentiment: Clinical and execution risks remain: The Phase 2 cohort was small (51 patients), results are topline/interim, and management’s forward statements note standard regulatory/clinical uncertainties — Phase 3 success is not guaranteed. MSN Coverage
• Negative Sentiment: Fundamentals and volatility: Ocugen remains a loss‑making, highly volatile biotech (historical swings, thin financials), so any setback or need for capital could pressure the stock further. (Background trading data provided by the user.)

Analyst Upgrades and Downgrades

OCGN has been the subject of a number of recent analyst reports. Canaccord Genuity Group initiated coverage on shares of Ocugen in a research note on Tuesday, March 17th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a report on Thursday, January 22nd. Wall Street Zen raised shares of Ocugen from a “sell” rating to a “hold” rating in a report on Saturday. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Ocugen in a research report on Thursday, March 5th. Finally, Oppenheimer began coverage on Ocugen in a report on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.00.

Ocugen Trading Down 11.2%

The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04. The company’s 50-day moving average is $1.73 and its 200 day moving average is $1.52. The company has a market cap of $611.53 million, a price-to-earnings ratio of -8.11 and a beta of 2.75.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The business had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.86 million. Research analysts predict that Ocugen, Inc. will post -0.2 EPS for the current year.

Institutional Trading of Ocugen

Several institutional investors have recently bought and sold shares of OCGN. Caitong International Asset Management Co. Ltd raised its stake in shares of Ocugen by 76,831.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 82,317 shares of the company’s stock worth $111,000 after buying an additional 82,210 shares during the period. Virtu Financial LLC purchased a new stake in Ocugen in the 4th quarter worth $106,000. NewEdge Advisors LLC raised its position in Ocugen by 69.0% during the fourth quarter. NewEdge Advisors LLC now owns 135,460 shares of the company’s stock worth $183,000 after acquiring an additional 55,305 shares during the period. Millennium Management LLC raised its position in Ocugen by 29.7% during the fourth quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock worth $7,285,000 after acquiring an additional 1,234,268 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in Ocugen during the fourth quarter valued at $196,000. 10.27% of the stock is owned by institutional investors and hedge funds.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.